Eye symptoms linked to AAV most common in GPA patients: Study

Eye symptoms related to ANCA-associated vasculitis (AAV) are most common among those with granulomatosis with polyangiitis (GPA), affecting more than one-third of these patients, a new study from China showed. “These insights collectively underscore the importance of consistent ocular [eye-related] assessments for AAV patients, enabling the monitoring of disease…

Adding Tavneos (avacopan) to standard maintenance treatment safely and effectively promotes disease remission in ANCA-associated vasculitis (AAV) patients, according to a real-world study involving five German centers. In fact, remission rates after one year of Tavneos treatment were higher than those reported in the Phase 3 ADVOCATE…

Using benralizumab — a medication approved in the U.S. for a rare type of asthma — off-label as an add-on to standard induction treatment resulted in a high rate of disease remission in people with eosinophilic granulomatosis with polyangiitis (EGPA) and severe asthma. That’s according to a real-world study in…

The production of new B-cells, a type of immune cell that helps fight infections but is also involved in the abnormal immune attacks that drive ANCA-associated vasculitis (AAV), is dysfunctional in people with the autoimmune disease, a study found. The findings could help shed light on the biological underpinnings…

ANCA-associated vasculitis (AAV) patients with neurological manifestations are more than three times more likely to have large blood vessel involvement (LVI), according to a multicenter study in France and Belgium. Data also showed that LVI most commonly affected the aorta — the large artery that delivers oxygen-rich blood to…

While it’s rare in children, ANCA-associated vasculitis (AAV)-related glomerulonephritis, that is, an inflammation of the glomeruli, the kidneys’ filtering units, is associated with high rates of kidney failure or death, a study shows. Also, scar tissue accumulating in the glomeruli, other kidney tissue abnormalities, and high protein levels in…

Treatment with the asthma medication montelukast may trigger eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV), a case-based review study suggests. The study, “Eosinophilic granulomatosis with polyangiitis and its association with montelukast: a case-based review,” was published in Clinical Rheumatology. AAV is a…

The U.S. Food and Drug Administration (FDA) has given Nkarta the green light to launch a clinical trial testing its cell therapy candidate NKX019 in people with ANCA-associated vasculitis (AAV) and other autoimmune disorders. The upcoming multicenter trial, dubbed Ntrust-2, is expected to initially recruit as many as…

Tavneos (avacopan) is better than the glucocorticoid prednisone at promoting disease remission, lowering relapse rates, and improving quality of life in ANCA-associated vasculitis (AAV) patients with active ear, nose, or throat (ENT) manifestations. That’s according to new subgroup analyses from the Phase 3 ADVOCATE clinical trial (NCT02994927).

Melodia Therapeutics has acquired the exclusive rights to develop, manufacture, and commercialize MDI-0151, a candidate therapy for hard-to-treat ANCA-associated vasculitis (AAV) and other disorders marked by overactivation of neutrophils, a type of immune cell. Melodia said it will “rapidly initiate” investigational new drug (IND)-enabling studies in preparation of a…